Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Trials Insight: 700036224

Trial Profile

Clinical Trials Insight: 700036224

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2009

At a glance

  • Drugs Vapendavir (Primary)
  • Indications Rhinovirus infections
  • Focus Therapeutic Use
  • Sponsors Biota Holdings
  • Most Recent Events

    • 14 Jun 2009 Planned number of patients changed from 240 to 41 actually enrolled, according to Biota Holdings media release.
    • 11 Jun 2009 Biota Holdings announced this study was successful in demonstrating proof-of-concept in humans according to a company media release.
    • 14 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top